Structural & Congenital Heart Disease

Investor’s Business Daily published a profile of Johns Hopkins physician Helen Brooke Taussig, MD, who overcame an initial rejection to medical school due to gender discrimination and went on to create the field of pediatric cardiology.

Adult congenital heart disease (ACHD)-related heart failure (HF) hospitalizations have increased in recent years and are associated with disproportionately higher costs, procedural burden and health resource use, according to new research published in the Journal of the American Heart Association.

Patients without electrocardiographic (ECG) evidence of left ventricular hypertrophy were significantly more likely to die in the two years after transcatheter aortic valve replacement (TAVR), researchers reported July 30 in Clinical Cardiology.

More than three-fourths of patients who received percutaneous balloon mitral valvuloplasty (PBMV) at a center in Brazil maintained procedural benefit over a median follow-up of 8.3 years, researchers reported in JACC: Cardiovascular Interventions.

CMS’s advisory committee appears to be split on whether procedural volume requirements should be required for centers to begin and maintain transcatheter aortic valve replacement (TAVR) programs.

Harvard University bioengineers have created a 3D model of a human’s left ventricle that they believe could be used to test drugs and study diseases.

Researchers from Weill Cornell Medicine in New York are worried the extension of transcatheter aortic valve replacement (TAVR) to younger, intermediate-risk patients is outpacing clinical evidence.

Mitral valve operations are the fastest-growing type of heart procedure, according to an analysis of the Society of Thoracic Surgeons’ Adult Cardiac Surgery database—but researchers believe interventions at earlier stages could further improve outcomes.

As CMS revisits the procedural volume requirements for centers to start and maintain a transcatheter aortic valve replacement (TAVR) program, several professional societies argued for direct TAVR experience to factor more strongly into the new standards.

Pediatric ventricular assist devices (VADs) have been associated with better survival to heart transplantation in recent years, but infants and those with congenital heart disease (CHD) continue to have worse outcomes, researchers reported in the Journal of the American College of Cardiology.

Valve-in-valve TAVR (ViV-TAVR) of a failed surgical valve was associated with comparable—and perhaps even better—clinical outcomes when compared to TAVR performed in native valves, according to a registry study published in the Journal of the American College of Cardiology.

With its potential to tap into a myriad of hospital services and departments, hypertrophic cardiomyopathy is drawing interest from medical centers committed to improving the lives of their patients and bolstering the bottom line.